March 22, 2018 09:22 AM EDT

AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

John Carroll

Editor & Founder

AbbVie’s stock $ABBV is getting hammered this morning after its $10 billion Rova-T program posted poor mid-stage results for third-line small cell lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Zealand’s ‘aspirational’ mission for its amylin drug to be first-line in obesity

Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3

Beam discloses first clinical data on base-edited sickle cell therapy, one patient death

J&J's Darzalex hits primary endpoint in Phase 3 early-stage multiple myeloma trial

Vertex makes money from sickle cell therapy Casgevy

Gene therapies don’t have to cost $4 million: New production platforms reduce development costs and risks

Ab­b­Vie shares tank on Ro­va-T flop, sud­den re­treat from ac­cel­er­at­ed ap­proval pitch

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

AbbVie shares tank on Rova-T flop, sudden retreat from accelerated approval pitch